Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 21, 2015 4:57pm

128 Views

Post# 23650198

RE:What causes heart disease?

tundup, thanks again for another excellent post and insight regarding sugar/carbhodrates in CVD. If you read Dr David Permutter's book "Grain Brain" you will see continuous reference to this.

Yes, this certainly bodes well for rvx-208 as well as the epigenetic platfroms within Zenith related to many other inflationary diseases.

Thanks again for continuing to provide excellent insight.
Cheers
TOINV

Bullboard Posts

Rock Tech notches official permit for German lithium refinery